Text Size

To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions

This study has been completed.
Sponsor:
Information provided by:
Sandoz
ClinicalTrials.gov Identifier:
NCT00913783
First received: June 2, 2009
Last updated: June 3, 2009
Last verified: June 2009
History of Changes
  Purpose

To demonstrate the relative bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride capsules under fasted conditions.


Condition Intervention Phase
Depression
 Drug: Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
Drug: Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparative, Randomized, 2-Way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fasted Conditions

Resource links provided by NLM:

MedlinePlus related topics: Depression
U.S. FDA Resources

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 34 days ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: November 1992
Study Completion Date: December 1992
Primary Completion Date: December 1992 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
 Drug: Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
Active Comparator: 2
Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
 Drug: Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00913783

Sponsors and Collaborators
Sandoz Inc.
Investigators
Principal Investigator: Richard Lalonde, Pharm.D. Phoenix International Life Science Inc.
  More Information

No publications provided

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc.
ClinicalTrials.gov Identifier: NCT00913783     History of Changes
Other Study ID Numbers: 920256
Study First Received: June 2, 2009
Last Updated: June 3, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Sandoz:
Antidepressant

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Clomipramine
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
 Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 18, 2013